Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebocontrolled …
CJ Fisher Jr, GJ Slotman, SM Opal, JP Pribble… - Critical care …, 1994 - journals.lww.com
Objectives: To evaluate the safety, pharmacokinetics, and efficacy of human recombinant
interleukin-1 receptor antagonist (IL-lra) in the treatment of patients with sepsis syndrome.
Design: Prospective, open-label, placebo-controlled, phase II, multicenter clinical trial using
three different doses of human recombinant ILlra. Setting: Twelve academic medical center
intensive care units in the United States. Patients: Ninety-nine patients with sepsis syndrome
or septic shock who received standard supportive care and antimicrobial therapy, in addition …
interleukin-1 receptor antagonist (IL-lra) in the treatment of patients with sepsis syndrome.
Design: Prospective, open-label, placebo-controlled, phase II, multicenter clinical trial using
three different doses of human recombinant ILlra. Setting: Twelve academic medical center
intensive care units in the United States. Patients: Ninety-nine patients with sepsis syndrome
or septic shock who received standard supportive care and antimicrobial therapy, in addition …